OMITTED

What the news leaves out.

← Omitted front page

Moderna Merck Melanoma Vaccine Shows Major Trial Success

7 sources · updated 2026-10-24
Left 71% Center 0% Right 29%
5 left · 0 center · 2 right

What happened

On Thursday, Moderna and Merck released full Phase 3 results for their personalized mRNA vaccine intismeran autogene after partial data leaked on social media, ahead of a Saturday presentation at the European Society for Medical Oncology conference in Madrid. In a trial of more than 1,100 Stage 3 melanoma patients whose tumors had been surgically removed, the vaccine plus Merck’s immunotherapy Keytruda reduced the risk of recurrence or death by 42 percent compared with Keytruda alone, and 82 percent of combination patients were alive without melanoma returning at two years versus 70 percent on Keytruda alone. The custom shot, built from each patient’s tumor mutations, also cut the risk of distant spread or death by 38 percent; a separate analysis found a 58 percent reduction in recurrence or death after the six-month vaccine regimen. Overall survival benefit has not yet been determined, and manufacturing each dose takes about six weeks. Moderna shares fell as much as 25 percent on the leak, while Merck shares fell about 1 percent.
Sourcing check · Mostly on the record · 7 articles

6 of 7 articles cite a named source for the story. It was on the record from the first report.

What these terms mean and how they're counted
On the record · names a source 6 of 7
On the record means the article cites a source by name for the story's main claim: a person, or an institution speaking officially, such as a company statement or a named agency's spokesperson. The opposite is an unnamed source. The count is how many of the counted articles cite at least one such source; the names are everyone named across them, each once however the articles spell it. Here: Dr. Hussein Tawbi, Dr. Dean Li, Moderna, Merck, Sekwon Jang and Merck and Moderna
Primary evidence · cites a document or data 2 of 7
Primary evidence means the article cites a record you could check yourself: a court filing or ruling, a dataset or report, a recording or transcript, an official statement or press release, market data. A quote is not a document. The count is how many articles cite one. Here: company report, clinical trial results
Credits another outlet 0 of 7
The article says the story comes from another outlet's reporting (“first reported by Reuters”). Those articles relay the story; they are not independent confirmation. Here: Each article presents its own reporting.
Unnamed sources 0 of 7
The main claim is attributed to people who are not identified: “people familiar with the matter”, “officials said”. The count is how many articles do this.
How it developed
When the first report landed and whether it named anyone; when the first named source and the first document appeared. Here: First report Oct 22, 21:52 UTC by CNBC, naming its source. First document 10 hours later, from New York Post (clinical trial results).
Not counted 0
Opinion, analysis and video pieces, and articles too short to assess. Every count above is out of the counted articles. An article republished under a new headline is one article.
This is about who is cited, not whether the story is true. Each source below says what it names. How we count
Omitted — what each side leaves out

Unpacked

Right-leaning coverage presents the recurrence result as a finished success, while left-leaning coverage reports that no one yet knows if patients live longer. The companies told CNBC it is still too early to determine overall survival. The New York Post says only that the trial continues to track longer-term outcomes. Left-leaning coverage is simply more complete on that limit. Left-leaning coverage led with Wall Street's selloff, and right-leaning coverage led with the medical claim. CNBC put the share plunge in the headline ahead of the trial data. The New York Post opened on a "first-of-its-kind" vaccine that reduces the chance tumors return. How does adding the vaccine after surgery compare with giving immunotherapy before the operation, which many eligible patients already receive?
Bottom line

Both sides printed a 42 percent cut in recurrence, but only left-leaning coverage told readers the companies cannot yet say whether patients live longer.

The receipts — 6 facts one side's coverage lacks
  • The companies said it is still too early to determine whether the treatment helps patients live longer overall. official statementin CNBC · absent from right-leaning coverage
  • The combination reduced the risk of cancer spreading to distant parts of the body or death by 38% compared with Keytruda alone. numberin CNBC · absent from right-leaning coverage
  • Of 1,749 patients screened for the trial, 17% did not have tumor samples big enough for a vaccine to be created. numberin NBC News · absent from right-leaning coverage
  • A separate analysis showed a 58% reduction in risk of recurrence or death after the six-month vaccine regimen. numberin CNBC · absent from right-leaning coverage
  • Each patient received nine custom vaccine doses given three weeks apart. numberin New York Post · absent from left-leaning coverage
  • The trial tested the vaccine after surgery with Keytruda and does not show whether that approach is more or less effective than immunotherapy given before surgery. contextin CNBC · absent from right-leaning coverage
The Left View
Left-leaning coverage framed a clash between clinically meaningful results and a steep sell-off driven by inflated investor expectations after Moderna shares had surged more than 530 percent year-to-date. CNBC reported that six melanoma specialists called the data a clinically meaningful advance that could become standard of care, with milder toxicity than other add-on treatments; Dr. Sekwon Jang said it “has the potential to be a major breakthrough,” while RBC’s Trung Huynh said the primary result landed at the “low end of investor expectations.” NBC News quoted Dr. Robert Vonderheide calling it a “game changer” and “the first step toward using cancer vaccines to their full potential,” while also reporting remaining questions on overall survival, longer follow-up, and scale—including that 17 percent of screened patients lacked tumor samples large enough for a vaccine. Coverage noted Moderna is finishing a regulatory filing aiming for approval next year, and that Merck’s Dean Li cautioned success in one tumor “does not give you a cabin or a village.”
The Right View
Right-leaning coverage presented the results as a clear scientific win rather than a market story. The New York Post called it a “first-of-its-kind” custom-brewed vaccine that “significantly” reduced recurrence risk and quoted trial investigator Dr. Hussein Tawbi: “The field has been looking for a win and I think this one is a big one.” Experts not involved in the study called it “a new frontier” and “a big step forward for science, for oncology, because this vaccine will apply to many different cancers.” Coverage highlighted the Nobel Prize-winning mRNA platform used in COVID-19 vaccines, a trial patient who remains cancer-free, talks with regulators about seeking approval, and that Moderna’s Massachusetts facility is already supplying doses for multiple studies, while noting the stock drop more briefly and that shares remained far above late-August levels.
Our Take (balanced)
The left’s strongest argument is that oncologists at multiple centers judged the trial a clinically meaningful advance—with relatively mild side effects and potential to become standard of care—even as the sell-off showed Wall Street had priced in a larger effect and still faces unanswered questions on overall survival, cost, and whether personalized manufacturing can scale; that case rests on specialist assessments plus the gap between a 42 percent result and a stock that had already surged hundreds of percent. The right’s strongest argument is that a first-of-its-kind personalized mRNA vaccine produced a statistically significant, durable reduction in melanoma recurrence in a large Phase 3 trial, which independent specialists described as a win the field had been seeking and a step that could extend to other cancers. The central unresolved tension is whether a result doctors call a major clinical advance is also a commercial and transformative one, given manufacturing complexity, still-unknown overall survival, and investor expectations that had already run far ahead of the data.

7 sources

More stories

The week's bottom lines, in your inbox

One email a week: the five stories that mattered and what they actually mean. Free.